1. Scrip
  2. >>R&D
  3. >>Clinical Trials

TULIP Fever: AstraZeneca Catches Cold With Disappointing Lupus Data

 
• By Alexandra Shimmings

Another one of AstraZeneca’s more left-field product candidates, its investigational lupus therapy anifrolumab, has disappointed at Phase III.

Dead tulip

The first of two Phase III TULIP trials of AstraZeneca PLC/MedImmune LLC’s investigational lupus therapy, anifrolumab, has missed its primary endpoint, casting the program in doubt.

Top-line data from the 52-week TULIP 1 study in adult patients with moderate-to-severe systemic lupus erythematosus (SLE) show the drug did not significantly reduce disease activity

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

More from R&D